- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2013 (2013), Article ID 278405, 13 pages
http://dx.doi.org/10.1155/2013/278405
Vitexicarpin Acts as a Novel Angiogenesis Inhibitor and Its Target Network
1MOE Key Laboratory of Bioinformatics and Bioinformatics Division, TNLIST, Department of Automation, Tsinghua University, Beijing 100084, China
2Joint Computational Center of Drug Discovery, Tianjin International Joint Academy of Biotechnology & Medicine, Tianjin 300457, China
Received 22 October 2012; Accepted 20 November 2012
Academic Editor: Weidong Zhang
Copyright © 2013 Bo Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
How to Cite this Article
Bo Zhang, Lu Liu, Shiwen Zhao, Xu Wang, Liyang Liu, and Shao Li, “Vitexicarpin Acts as a Novel Angiogenesis Inhibitor and Its Target Network,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 278405, 13 pages, 2013. doi:10.1155/2013/278405